{'52WeekChange': 0.049085617,
 'SandP52WeekChange': 0.0644362,
 'address1': 'PO Box 666',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 10.9,
 'askSize': 1400,
 'averageDailyVolume10Day': 803475,
 'averageVolume': 1056300,
 'averageVolume10days': 803475,
 'beta': None,
 'beta3Year': None,
 'bid': 10.63,
 'bidSize': 1000,
 'bookValue': 1.493,
 'category': None,
 'circulatingSupply': None,
 'city': 'Oldwick',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 11.64,
 'dayLow': 10.52,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 443790208,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 13.813857,
 'fiftyTwoWeekHigh': 18.5,
 'fiftyTwoWeekLow': 4.72,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 34101305,
 'forwardEps': -1.57,
 'forwardPE': -6.9426746,
 'fromCurrency': None,
 'fullTimeEmployees': 19,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.25634,
 'heldPercentInstitutions': 0.21765,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/proventionbio.com',
 'longBusinessSummary': 'Provention Bio, Inc., a clinical stage '
                        'biopharmaceutical company, focuses on the development '
                        'and commercialization of therapeutics and solutions '
                        'to intercept and prevent immune-mediated diseases. '
                        'Its products candidates include PRV-031 teplizumab '
                        'and monoclonal antibodies (mAb) that is in Phase III '
                        'clinical trial for the interception of type one '
                        'diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, '
                        'which is in Phase IIa clinical trial for the '
                        "treatment of Crohn's disease; PRV-3279, which has "
                        'completed Phase 1b clinical trial for the treatment '
                        'of lupus; PRV-101, a coxsackie virus B (CVB) vaccine '
                        'for the prevention of acute CVB infections and onset '
                        'of T1D; and PRV-015, which is in phase IIb clinical '
                        'trial for the treatment of gluten-free diet '
                        'non-responding celiac disease. The company has a '
                        'license and collaboration agreement with Amgen Inc. '
                        'for PRV-015, a novel anti-IL-15 monoclonal antibody '
                        'being developed for the treatment of gluten-free diet '
                        'non-responsive celiac disease. Provention Bio, Inc. '
                        'was incorporated in 2016 and is based in Oldwick, New '
                        'Jersey.',
 'longName': 'Provention Bio, Inc.',
 'market': 'us_market',
 'marketCap': 611058368,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_429733643',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -44895000,
 'nextFiscalYearEnd': 1640908800,
 'open': 11,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '908 336 0360',
 'previousClose': 11.08,
 'priceHint': 2,
 'priceToBook': 7.3007364,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 11.64,
 'regularMarketDayLow': 10.52,
 'regularMarketOpen': 11,
 'regularMarketPreviousClose': 11.08,
 'regularMarketPrice': 11,
 'regularMarketVolume': 1068451,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 56060400,
 'sharesPercentSharesOut': 0.091400005,
 'sharesShort': 5125067,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2525362,
 'shortName': 'Provention Bio, Inc.',
 'shortPercentOfFloat': 0.1009,
 'shortRatio': 2.88,
 'startDate': None,
 'state': 'NJ',
 'strikePrice': None,
 'symbol': 'PRVB',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.036,
 'twoHundredDayAverage': 12.706835,
 'volume': 1068451,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.proventionbio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '08858'}